NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced new data from the AUGMENT-101 trial of their menin inhibitor, Revuforj® (revumenib), during the 30th European Hematology Association Annual Congress. These findings have led to the FDA approval of Revuforj for patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. Additionally, these results underpin a supplemental New Drug Application (NDA) submitted to the FDA for treating relapsed or refractory mutant NPM1 acute myeloid leukemia $(AML.AU)$, addressing a significant unmet medical need.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。